Home > Publications Database > Genetic assessment of apolipoprotein E polymorphism and PRNP genotypes in rapidly progressive dementias in Pakistan. > print

001     274007
005     20250120102329.0
024 7 _ |a 10.1080/19336896.2024.2439598
|2 doi
024 7 _ |a pmid:39654135
|2 pmid
024 7 _ |a 1933-6896
|2 ISSN
024 7 _ |a 1933-690X
|2 ISSN
024 7 _ |a altmetric:172006564
|2 altmetric
037 _ _ |a DZNE-2024-01435
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Rasheed, Urwah
|b 0
245 _ _ |a Genetic assessment of apolipoprotein E polymorphism and PRNP genotypes in rapidly progressive dementias in Pakistan.
260 _ _ |a London [u.a.]
|c 2024
|b Taylor & Francis
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1734533745_3774
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Rapidly progressive dementias (RPDs) are a type of fatal dementias that cause rapid progression of neuronal dysfunction. This study aimed to assess the prevalence of APOE genotypes (ε2, ε3, ε4) and PRNP mutations (E200K, M129V) in the general population of Pakistan because of their association with RPDs, including Rapidly Progressive Alzheimer's Disease (rpAD) and Creutzfeldt-Jakob Disease (CJD). Blood samples (n = 100) were collected from healthy Pakistani population and the stated mutations were assessed using polymerase chain reaction. In the analysis of the APOE genotype, ε3/ε3 genotype was the most common (95%), followed by ε3/ε4 (5%) and ε2 allele was completely absent. A low frequency of ε4 allele and the absence of a protective ε2 allele is associated with an increased risk of rpAD. In the case of PRNP mutations, the most common genotype was M129-Ε200 (71%) and V129-Ε200 (29%). E200K mutation was completely absent from the given population. It is noteworthy that the MM homozygous genotype was present in 71 samples, VV genotype was present in 29. Homozygosity on codon 129, as observed in most of our samples, has been associated with more efficient production of PrPSc and disease pathology. This study provides preliminary data indicating that rpAD and CJD pose a significant threat to the Pakistani population.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Creutzfeldt-Jakob disease
|2 Other
650 _ 7 |a incidence
|2 Other
650 _ 7 |a rapidly progressive Alzheimer’s disease
|2 Other
650 _ 7 |a rapidly progressive dementia
|2 Other
650 _ 7 |a Prion Proteins
|2 NLM Chemicals
650 _ 7 |a PRNP protein, human
|2 NLM Chemicals
650 _ 7 |a Apolipoproteins E
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Pakistan
|2 MeSH
650 _ 2 |a Prion Proteins: genetics
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Apolipoproteins E: genetics
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Polymorphism, Genetic: genetics
|2 MeSH
650 _ 2 |a Creutzfeldt-Jakob Syndrome: genetics
|2 MeSH
650 _ 2 |a Dementia: genetics
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Alleles
|2 MeSH
650 _ 2 |a Gene Frequency: genetics
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
700 1 _ |a Khalid, Minahil
|0 0009-0006-4684-8455
|b 1
700 1 _ |a Noor, Aneeqa
|0 P:(DE-2719)9001208
|b 2
700 1 _ |a Saeed, Umar
|0 0000-0002-9740-0371
|b 3
700 1 _ |a Uppal, Rizwan
|0 0000-0003-1599-651X
|b 4
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 5
|e Last author
773 _ _ |a 10.1080/19336896.2024.2439598
|g Vol. 18, no. 1, p. 1 - 7
|0 PERI:(DE-600)2267671-5
|n 1
|p 1 - 7
|t Prion
|v 18
|y 2024
|x 1933-6896
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274007/files/DZNE-2024-01435.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274007/files/DZNE-2024-01435.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274007
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9000358
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-25
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-17T13:48:23Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-17T13:48:23Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-17T13:48:23Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1440011-1
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21